Erdafitinib (BioDeep_00000178775)
human metabolite blood metabolite
代谢物信息卡片
化学式: C25H30N6O2 (446.24301199999996)
中文名称: 厄达替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
InChI: InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- PubChem: 67462786
- HMDB: HMDB0251903
- DrugBank: DB12147
- ChEMBL: CHEMBL3545376
- Wikipedia: Erdafitinib
- CAS: 1346242-81-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Tarek Elawady, Alaa Khedr, Nahed El-Enany, Fathalla Belal. Utility of Kolliphor RH 40 in micellar sensitized fluorescence of the novel tyrosine kinase inhibitor 'Erdafitinib': Application to human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2022 Oct; 278(?):121327. doi:
10.1016/j.saa.2022.121327. [PMID: 35567824] - Anne-Gaëlle Dosne, Elodie Valade, Kim Stuyckens, Peter De Porre, Anjali Avadhani, Anne O'Hagan, Lilian Y Li, Daniele Ouellet, Ruben Faelens, Quentin Leirens, Italo Poggesi, Juan Jose Perez Ruixo. Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.
CPT: pharmacometrics & systems pharmacology.
2022 05; 11(5):569-580. doi:
10.1002/psp4.12727. [PMID: 34755484] - Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O'Hagan, Lilian Y Li, Daniele Ouellet, Juan Jose Perez Ruixo. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Cancer chemotherapy and pharmacology.
2022 02; 89(2):151-164. doi:
10.1007/s00280-021-04381-4. [PMID: 34977972] - E M Tosca, N Terranova, K Stuyckens, A G Dosne, T Perera, J Vialard, P King, T Verhulst, J J Perez-Ruixo, P Magni, I Poggesi. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
Cancer chemotherapy and pharmacology.
2022 01; 89(1):117-128. doi:
10.1007/s00280-021-04370-7. [PMID: 34786600] - Loeckie De Zwart, Jan Snoeys, Frank Jacobs, Lilian Y Li, Italo Poggesi, Peter Verboven, Ivo Goris, Ellen Scheers, Inneke Wynant, Mario Monshouwer, Rao N V S Mamidi. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
CPT: pharmacometrics & systems pharmacology.
2021 09; 10(9):1107-1118. doi:
10.1002/psp4.12682. [PMID: 34273250] - Mohd Amir, Mohd Aamir Qureshi, Saleem Javed. Biomolecular interactions and binding dynamics of tyrosine kinase inhibitor erdafitinib, with human serum albumin.
Journal of biomolecular structure & dynamics.
2021 Jul; 39(11):3934-3947. doi:
10.1080/07391102.2020.1772880. [PMID: 32448054] - Kaili Jiang, Xia Tang, Jing Guo, Rui He, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Yuting Wang, Xiaomei Ren, Ke Ding, Zhang Zhang. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.
Cancer medicine.
2021 07; 10(14):4874-4884. doi:
10.1002/cam4.4041. [PMID: 34114373] - Tarek Elawady, Alaa Khedr, Nahed El-Enany, Fathalla Belal. HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 May; 1171(?):122629. doi:
10.1016/j.jchromb.2021.122629. [PMID: 33752054] - Mathijs P Scholtes, Arnout R Alberts, Iris G Iflé, Paul C M S Verhagen, Astrid A M van der Veldt, Tahlita C M Zuiverloon. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
International journal of molecular sciences.
2021 Mar; 22(6):. doi:
10.3390/ijms22062832. [PMID: 33799514] - Ellen Scheers, Carine Borgmans, Chi Keung, Hilde Bohets, Inneke Wynant, Italo Poggesi, Filip Cuyckens, Laurent Leclercq, Rao N V S Mamidi. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Feb; 51(2):177-193. doi:
10.1080/00498254.2020.1821123. [PMID: 32902324] - Anne-Gaelle Dosne, Elodie Valade, Kim Stuyckens, Lilian Y Li, Daniele Ouellet, Juan Jose Perez-Ruixo. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Journal of clinical pharmacology.
2020 04; 60(4):515-527. doi:
10.1002/jcph.1547. [PMID: 31742712] - Lilian Y Li, Yue Guo, Martha Gonzalez, Daniele Ouellet. Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis.
Journal of clinical pharmacology.
2020 03; 60(3):391-399. doi:
10.1002/jcph.1529. [PMID: 31602692] - Kiera Roubal, Zin W Myint, Jill M Kolesar. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2020 Feb; 77(5):346-351. doi:
10.1093/ajhp/zxz329. [PMID: 32073123] - Italo Poggesi, Lilian Y Li, James Jiao, Peter Hellemans, Freya Rasschaert, Loeckie de Zwart, Jan Snoeys, Marc De Meulder, Rao N V S Mamidi, Daniele Ouellet. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
European journal of drug metabolism and pharmacokinetics.
2020 Feb; 45(1):101-111. doi:
10.1007/s13318-019-00581-9. [PMID: 31673875] - Elodie Valade, Anne-Gaëlle Dosne, Hong Xie, Robert Kleiman, Lilian Y Li, Juan José Perez-Ruixo, Daniele Ouellet. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Cancer chemotherapy and pharmacology.
2019 09; 84(3):621-633. doi:
10.1007/s00280-019-03896-1. [PMID: 31280362] - Shuyan Dai, Zhan Zhou, Zhuchu Chen, Guangyu Xu, Yongheng Chen. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors.
Cells.
2019 06; 8(6):. doi:
10.3390/cells8060614. [PMID: 31216761] - Tomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, Hidehisa Noguchi, Masayuki Aoki, Toshihiko Doi. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Investigational new drugs.
2018 06; 36(3):424-434. doi:
10.1007/s10637-017-0514-4. [PMID: 28965185] - Jayaprakash D Karkera, Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph C Portale, Ademi Santiago-Walker, Christopher H Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng R Luo, John D Alvarez, Matthew V Lorenzi, Suso J Platero. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
Molecular cancer therapeutics.
2017 08; 16(8):1717-1726. doi:
10.1158/1535-7163.mct-16-0518. [PMID: 28416604]